Skip to main content
Applied Microbiology logoLink to Applied Microbiology
. 1969 Feb;17(2):202–207. doi: 10.1128/am.17.2.202-207.1969

In Vitro Effect of Rifampin on Mycobacteria

Victor Lorian 1,2,1, Maxwell Finland 1,2
PMCID: PMC377649  PMID: 4975656

Abstract

Rifampin inhibited 20 strains of Mycobacterium tuberculosis in concentrations of 0.005 to 0.02 μg/ml in 7H-9 broth with Tween 80 and killed all or nearly all of the inoculum in four to eight times greater concentrations. In the same medium without Tween 80, as well as on 7H-10 agar, about 16 to 64 times these amounts were required to produce the same effect. Rifampin was also active against M. kansasii and some of the nonchromogenic mycobacteria. The incidence of mycobacterial cells resistant to rifampin within the cultures studied was in the range of one to four per 108 to 109 colony-forming units with concentrations of 4 to 125 μg of rifampin per ml. Only one of the Battey cultures and that of M. fortuitum yielded cells resistant to rifampin at 125 μg/ml but not at 500 μg/ml. The same strains yielded more than double that number of organisms resistant to streptomycin and up to 100 times more organisms resistant to isoniazid. All three drugs stopped the growth or reduced the mycobacterial population in growing cultures after contact for 24 to 48 hr. Complete inhibition of growth was produced by rifampin at 1.0 μg/ml in an average of 6 days and by streptomycin at 5.0 μg/ml in 3 days. After an average contact of 10.7 days with rifampin, five of seven strains resumed growth and all strains began regrowth after exposure to streptomycin for 9.4 days. The marked susceptibility of M. tuberculosis and of atypical mycobacteria to rifampin in vitro and the relatively low incidence of resistant mutants suggests that this agent may have clinical usefulness in the treatment of tuberculosis and some other mycobacterioses.

Full text

PDF
202

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arioli V., Pallanza R., Furesz S., Carniti G. Rifampicin: a new rifamycin. I. Bacteriological studies. Arzneimittelforschung. 1967 May;17(5):523–529. [PubMed] [Google Scholar]
  2. Hobby G. L., Lenert T. F. The antimycobacterial activity of rifampin. Am Rev Respir Dis. 1968 Apr;97(4):713–714. doi: 10.1164/arrd.1968.97.4.713. [DOI] [PubMed] [Google Scholar]
  3. Kradolfer F. Uber eine neue Klasse von baktericid wirkenden Antibiotica unter spezieller Berücksichtigung von Rifampicin. Schweiz Med Wochenschr. 1968 Apr 20;98(16):622–627. [PubMed] [Google Scholar]
  4. McCabe W. R., Lorian V. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am J Med Sci. 1968 Oct;256(4):255–265. doi: 10.1097/00000441-196810000-00007. [DOI] [PubMed] [Google Scholar]
  5. Sensi P., Maggi N., Füresz S., Maffii G. Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother (Bethesda) 1966;6:699–714. [PubMed] [Google Scholar]
  6. TIMBAL M. T. Rifomycin. II. Antibacterial activity of rifomycin B. Antibiot Annu. 1959;7:271–276. [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES